Behavioural Intervention
FES Cycling for Multiple Sclerosis
This trial tests whether using electrical impulses to stimulate muscles during cycling can help people with MS who have trouble moving. The goal is to see if this approach can improve muscle strength and mobility better than current treatments.
Brain-Machine Interface
Brain-Computer Interface Device for Severe Neurological Disorders
This trial is testing a method that uses sensors on the brain to help people with severe neurological disorders control devices and speak. The sensors pick up brain signals and translate them into actions or speech. This could help those who struggle with movement and communication due to their condition.
Behavioural Intervention
Behavioral Intervention for Multiple Sclerosis
This trial tests an online program to help people with MS become more active. The program aims to improve their mobility, thinking skills, and overall well-being by boosting their confidence and setting clear goals. Researchers believe this will lead to lasting positive changes in their physical activity and quality of life.
Popular Filters
Trials for MS Patients
Retinal Imaging for Neurodegenerative Disease
This trial uses special cameras to take detailed pictures of the back of the eye in people with cognitive impairments or neurodegenerative diseases. Researchers analyze these images to find early signs of these diseases by examining tiny blood vessels in the eye.
Combination Therapies for Multiple Sclerosis
This trial tests four different drugs, alone or in combination, on adults with progressive multiple sclerosis who are not responding well to current treatments. The goal is to see if these drugs can reduce harmful inflammation and immune activity in the brain and spinal fluid.
Antioxidant
N-Acetyl Cysteine for Multiple Sclerosis
This trial is testing whether NAC, a cell-protecting supplement, can help MS patients by reducing cell damage in the brain. MS patients often experience nerve cell damage, and NAC may help by boosting a protective substance called glutathione. NAC has been explored in previous studies for its potential to improve brain glucose metabolism and blood flow in MS patients.
Trials for Mild Cognitive Impairment Patients
Retinal Imaging for Neurodegenerative Disease
This trial uses special cameras to take detailed pictures of the back of the eye in people with cognitive impairments or neurodegenerative diseases. Researchers analyze these images to find early signs of these diseases by examining tiny blood vessels in the eye.
EMR-Based Treatment for Neurological Disorders
This trial will study 10 common neurological disorders at NorthShore University HealthSystem using electronic medical records (EMR). They aim to show that assigning treatments based on specific subgroups, obtaining electronic consent
Procedure
Deep Brain Stimulation for Parkinson's Disease
This trial is testing different types of deep brain stimulation to see which is most effective in treating Parkinson's, essential tremor, and multiple sclerosis. The results will help design more effective stimulation patterns and aid in understanding how DBS works.
Cannabinoid
Medical Cannabis for Chronic Pain
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Behavioural Intervention
Movement-2-Music Exercise Program for Mobility Disabilities
This trial is testing the effects of an innovative exercise program, movement-2-music (M2M), on health and fitness outcomes in adults with physical/mobility disabilities. One hundred and eight participants will be recruited and randomly enrolled into one of two groups: M2M or waitlist control. The primary aim of this study is to determine the effects of the 12-week M2M program on health and fitness in participants with physical/mobility disabilities. The study will also compare the observed effects of the program to a previous M2M study, and test whether adherence (attendance to the 12-week program) affects the
Phase 3 Trials
Sphingosine-1-phosphate receptor modulator
Ozanimod for Multiple Sclerosis
This trial will test the effects of ozanimod on cognitive processing speed in 250 subjects with relapsing multiple sclerosis over the course of 36 months. The primary efficacy endpoint is the proportion of subjects with a clinically meaningful increase in raw score of ≥ 4 points or 10% from baseline (improved). There is no planned protocol extension following the end of the study.
Monoclonal Antibodies
Ofatumumab + Siponimod vs Fingolimod for Pediatric Multiple Sclerosis
This trial tests three medications in children and teens with multiple sclerosis to find effective treatments. The drugs work by reducing harmful immune cells or preventing them from attacking the nervous system.
Monoclonal Antibodies
High-Dose Ocrelizumab for Multiple Sclerosis
This trial is testing if a higher dose of ocrelizumab given through an IV drip is more effective and safe for patients with Primary Progressive Multiple Sclerosis (PPMS). The drug works by reducing harmful immune cells to potentially slow down the disease. Ocrelizumab is the first drug approved for treating both relapsing and primary progressive forms of multiple sclerosis.
Trials With No Placebo
Retinal Imaging for Neurodegenerative Disease
This trial uses special cameras to take detailed pictures of the back of the eye in people with cognitive impairments or neurodegenerative diseases. Researchers analyze these images to find early signs of these diseases by examining tiny blood vessels in the eye.
Combination Therapies for Multiple Sclerosis
This trial tests four different drugs, alone or in combination, on adults with progressive multiple sclerosis who are not responding well to current treatments. The goal is to see if these drugs can reduce harmful inflammation and immune activity in the brain and spinal fluid.
Antioxidant
N-Acetyl Cysteine for Multiple Sclerosis
This trial is testing whether NAC, a cell-protecting supplement, can help MS patients by reducing cell damage in the brain. MS patients often experience nerve cell damage, and NAC may help by boosting a protective substance called glutathione. NAC has been explored in previous studies for its potential to improve brain glucose metabolism and blood flow in MS patients.
View More Related Trials
Frequently Asked Questions
Introduction to multiple sclerosis
What are the top hospitals conducting multiple sclerosis research?
When it comes to advancing treatment options for multiple sclerosis (MS), several hospitals across the United States are leading the way in groundbreaking clinical trials. In Cleveland, Ohio, the renowned Cleveland Clinic is actively involved in five ongoing MS trials and has an impressive track record of 26 completed trials since their first recorded endeavor in 2005. Meanwhile, in Oklahoma City, the Oklahoma Medical Research Foundation is making significant contributions with four active MS trials and a total of 11 completed studies since initiating their first trial in 2011.
In Chicago, Illinois, the University of Illinois at Chicago is also dedicated to pioneering new treatments for MS through its participation in four ongoing clinical trials. Their commitment dates back to 2003 when they conducted their initial trial on this complex neurological disorder.
Another prominent institution contributing to our understanding of MS is the National Institutes of Health Clinical Center located in Bethesda, Maryland. With four active clinical trials and a remarkable history involving 15 previous investigations dating all the way back to their first recorded trial on MS in 1992.
Lastly but not least important,the University of Texas Southwestern Medical Center situated Dallas takes pride into offering three current clinical tests while holding around thirteen former inquiries;theirs can be traced back only seventeen years ago where they initiated exploration into managing this condition from as early as year2004
These hospitals serve as beacons of hope for those affected by multiple sclerosis by pushing forward medical boundaries through innovative research initiatives. The collective efforts displayed by these institutions underscore our commitment towards finding better treatment options and ultimately improving quality of life for individuals living with this chronic autoimmune disease
Which are the best cities for multiple sclerosis clinical trials?
When it comes to multiple sclerosis clinical trials, several cities emerge as leading hubs for research and development. Philadelphia, Pennsylvania stands out with 17 active trials focusing on treatments like RPC-1063, Ocrelizumab, and BNT162b2. New york, New York follows closely behind with 15 ongoing studies exploring interventions such as Ocrelizumab and Bivalent + Continue IS (MTX). Additionally, Cleveland, Ohio hosts 11 active trials investigating treatments like RPC-1063 and Cohort B. These cities serve as centers of excellence in multiple sclerosis research, offering individuals affected by the condition access to innovative therapies that hold promise for improved outcomes.
Which are the top treatments for multiple sclerosis being explored in clinical trials?
Multiple sclerosis (MS) research is at the forefront of medical advancements, with several promising treatments currently under exploration in clinical trials. The leading contenders include:
-
Ocrelizumab: Demonstrating its potential, ocrelizumab is involved in seven active trials and has been a part of 48 multiple sclerosis studies since it was first listed in 2008.
-
HB-adMSCs: A newcomer on the scene, HB-adMSCs are being investigated in one ongoing trial for MS. This therapy shows great promise as it enters the world of clinical research.
-
Phase 3; MYOBLOC: Another recent addition to the list, phase 3 MYOBLOC holds significant potential for treating multiple sclerosis. Currently engaged in one active trial, this treatment option warrants close attention from researchers and patients alike.
These cutting-edge therapies offer hope for individuals living with MS and highlight the continuous efforts made to find effective solutions against this complex neurological disorder.
What are the most recent clinical trials for multiple sclerosis?
Recent clinical trials offer promising prospects for individuals living with multiple sclerosis. One such trial focuses on Clemastine Fumarate, which has progressed to Phase 2 after successful results in Phase 1. Another study examines the effectiveness of PIPE-791 as a potential treatment option for multiple sclerosis patients following positive outcomes in its Phase 1 trial. Additionally, an ongoing Phase 2 trial is investigating a novel treatment arm specifically tailored for individuals with multiple sclerosis. These advancements bring hope and optimism to those affected by this debilitating condition, showcasing the dedication of researchers and medical professionals towards improving patient care and quality of life.
What multiple sclerosis clinical trials were recently completed?
In recent years, several clinical trials have concluded in their quest to advance the understanding and treatment options for multiple sclerosis (MS). Notable among them is a trial sponsored by the University of Utah which focused on MRI Brain and Cervical Spine, completed in June 2022. Additionally, Mapi Pharma Ltd.'s GA Depot trial finished in September 2019, followed closely by Columbia University's Aspirin 650mg Oral Capsule study which concluded in April of that same year. Other significant trials include Novartis Pharmaceuticals' Siponimod (February 2019), Biogen's Natalizumab (November 2018), Tisch Multiple Sclerosis Research Center of New york's Intrathecal MSC-NP injection (September 2018), and Johns Hopkins University's Tauroursodeoxycholic Acid research (June 2018). These collective efforts demonstrate ongoing dedication towards advancing treatments for individuals living with MS.